Medtronic Heart Valves Division
United Statesfrom the FDA registration address FDA establishment FEI 2025587
- Devices
- 0
- Registrations
- FDA
- FDA recalls
- 74 ongoing
Company details
- FDA FEI number
- 2025587
- Address
- 1851 EAST DEERE AVE., Santa Ana, CA, 92705
FDA recalls
Recalls initiated per year
- 2017 0
- 2018 0
- 2019 0
- 2020 3
- 2021 3
- 2022 0
- 2023 0
- 2024 0
- 2025 0
- 2026 1
2026
- 22 May 2026 Z-2624-2026 Class I Ongoing Devices containing inner shaft assemblies from specific manufacturing lots may have an increased potential for distal tip detachment from the delivery system under certain procedural or anatomical conditions due to a manufacturing issue.
Full distribution text
- 22 May 2026 Z-2624-2026 Class I Ongoing Devices containing inner shaft assemblies from specific manufacturing lots may have an increased potential for distal tip detachment from the delivery system under certain procedural or anatomical conditions due to a manufacturing issue.
2021
- 11 Jun 2021 Z-2041-2021 Class II Ongoing Due to reports of actuator separation for various delivery catheter systems. Affected products were manufactured before July 11, 2020.
Full distribution text
- 11 Jun 2021 Z-2042-2021 Class II Ongoing Due to reports of actuator separation for various delivery catheter systems. Affected products were manufactured before July 11, 2020.
Full distribution text
- 11 Jun 2021 Z-2043-2021 Class II Ongoing Due to reports of actuator separation for various delivery catheter systems. Affected products were manufactured before July 11, 2020.
Full distribution text
- 11 Jun 2021 Z-2041-2021 Class II Ongoing Due to reports of actuator separation for various delivery catheter systems. Affected products were manufactured before July 11, 2020.
2020
- 23 Oct 2020 Z-0559-2021 Class II Terminated Potential for Transcatheter Aortic Valve (TAV) leaflet damage when performing a post-implant balloon dilatation (PID).
Full distribution text
- 23 Oct 2020 Z-0560-2021 Class II Terminated Potential for Transcatheter Aortic Valve (TAV) leaflet damage when performing a post-implant balloon dilatation (PID).
Full distribution text
- 23 Oct 2020 Z-0561-2021 Class II Terminated Potential for Transcatheter Aortic Valve (TAV) leaflet damage when performing a post-implant balloon dilatation (PID).
Full distribution text
- 23 Oct 2020 Z-0559-2021 Class II Terminated Potential for Transcatheter Aortic Valve (TAV) leaflet damage when performing a post-implant balloon dilatation (PID).